STAT April 15, 2021
Trying to gauge the value of new drugs and devices is becoming increasingly important in the U.S. health care system, something that other countries have done explicitly for years.
Pressure to get value assessment right is accelerating. The Biden administration is reportedly considering creating a health technology assessment board to evaluate drug and other health care pricing. But if it doesn’t incorporate essential elements into the definition of value — such as data on underrepresented groups and impacts on health equity — it may worsen the health disparities that many in the health care community are attempting to eliminate.
Structural deficiencies in the models that underlie value assessment have perpetuated health inequities. Communities of color and other groups are generally...
Today's Sponsors
Today's Sponsor